National Centre for Pharmacoeconomics

National Centre for
Pharmacoeconomics

NCPE Ireland

Hydroxycarbamide (Siklos®) is indicated for use in the prevention of painful, recurrent vaso-occlusive crises, including acute chest syndrome, in adults, adolescents and children over 2 years of age suffering from symptomatic sickle-cell disease.

Rapid Review

Commenced Completed Outcome
22/08/2011 06/09/2011 Full Pharmacoeconomic Evaluation not Recommended